Incyte's Phase 3 trial finds promising results for Monjuvi in combination therapy for relapsed/refractory follicular lymphoma, surpassing PFS primary endpoint.

Incyte's Phase 3 inMIND trial shows promising results for Monjuvi (tafasitamab) in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, exceeding primary endpoint of progression-free survival (PFS). Incyte plans to submit a supplemental marketing application by year-end. Monjuvi, in combination with Revlimid, is already approved for diffuse large B-cell lymphoma.

August 16, 2024
7 Articles